Argitalpenak (21) GLORIA PÉREZ RUS argitalpenak

2020

  1. COVID-19 coagulopathy: An in-depth analysis of the coagulation system

    European Journal of Haematology, Vol. 105, Núm. 6, pp. 741-750

  2. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry

    Journal of Internal Medicine, Vol. 287, Núm. 1, pp. 32-41

  3. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 8, Núm. 3, pp. 353-359.e1

  4. Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin

    Clinical and Translational Oncology, Vol. 22, Núm. 8, pp. 1312-1320

2019

  1. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

2018

  1. Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry

    Journal of Thrombosis and Thrombolysis, Vol. 46, Núm. 4, pp. 551-558

2015

  1. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the lower limbs

    American Journal of Medicine, Vol. 128, Núm. 1, pp. 90.e9-90.e15

  2. Venous thromboembolism in patients immobilised at home

    European Respiratory Journal

2014

  1. A new case of successful outcome of pregnancy in a carrier of homozygous type II (L99F) antithrombin deficiency

    Blood Coagulation and Fibrinolysis, Vol. 25, Núm. 1, pp. 74-76

2012

  1. Rozrolimupab, amixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

    Blood, Vol. 120, Núm. 18, pp. 3670-3676

2010

  1. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: A study of the Spanish PETHEMA group

    Haematologica, Vol. 95, Núm. 8, pp. 1317-1324

2001

  1. Anemias hemolíticas de patogenia inmunológica. Mecanismos etiopatogénicos. Clasificación, clínica y diagnóstico. Manejo terapéutico

    Medicine: Programa de Formación Médica Continuada Acreditado, Vol. 8, Núm. 51, pp. 2703-2710

1997

  1. Copper deficiency with pancytopenia due to enteral nutrition through jejunostomy

    Clinical Nutrition, Vol. 16, Núm. 3, pp. 129-131

1994

  1. Peripheral thrombocytopenia, accessory spleen and hodgkin’s disease: An unusual combination

    Acta Haematologica, Vol. 91, Núm. 1, pp. 35-36

1990

  1. Methemoglobinemia with a probable sulfhemoglobinemia after phenylhydrazine ingestion: Response to a partial exchange transfusion

    Biologia y Clinica Hematologica, Vol. 12, Núm. 3, pp. 87-88

  2. Myelodysplastic syndromes. Hematologic phenotypes, cytogenetic expression and clinical course in 133 cases (1979-1989)

    Sangre, Vol. 35, Núm. 4, pp. 267-275

1987

  1. Los síndromes mielodisplásticos como estados preleucémicos.

    Sangre, Vol. 32, Núm. 6, pp. 715-730

1986

  1. La histiocitosis hemofagocítica como "segundo acontecimiento hematológico" de una leucemia aguda linfoblástica nula.

    Revista clinica espanola, Vol. 178, Núm. 3, pp. 129-134

1985

  1. Acute lymphoblastic leukaemia in adults: results of a ‘total‐therapy’programme in 47 patients over 15 years old

    British Journal of Haematology, Vol. 59, Núm. 4, pp. 689-696

1984

  1. Biological significance of nonlymphocytic oligoblastic leukemia: Cytokinetic behavior of dividing granulocytic precursors in 11 patients

    Acta Haematologica, Vol. 72, Núm. 2, pp. 105-110